These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2126028)

  • 41. Measles immunization strategies for an epidemiologically heterogeneous population: the Israeli case study.
    Agur Z; Danon YL; Anderson RM; Cojocaru L; May RM
    Proc Biol Sci; 1993 May; 252(1334):81-4. PubMed ID: 8391705
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Measles immunization: early two-doses policy experience.
    al-Mazrou YY; al-Jeffri M; Ahmed OM; Aziz KM; Mishkas AH
    J Trop Pediatr; 1999 Apr; 45(2):98-104. PubMed ID: 10341504
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost effectiveness of a targeted age-based West Nile virus vaccination program.
    Shankar MB; Staples JE; Meltzer MI; Fischer M
    Vaccine; 2017 May; 35(23):3143-3151. PubMed ID: 28456529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated.
    Sugerman DE; Barskey AE; Delea MG; Ortega-Sanchez IR; Bi D; Ralston KJ; Rota PA; Waters-Montijo K; Lebaron CW
    Pediatrics; 2010 Apr; 125(4):747-55. PubMed ID: 20308208
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Estimate of the cost/benefit ratio of measles vaccination].
    Cárdenas Ayala VM; Ruiz Matus C; Cabrera Coello L; Montesano Castellanos R; Garrido Lozada MT; Olvera Castillo R; Díaz Ortega JL
    Salud Publica Mex; 1989; 31(6):735-44. PubMed ID: 2516660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The average cost of measles cases and adverse events following vaccination in industrialised countries.
    Carabin H; Edmunds WJ; Kou U; van den Hof S; Nguyen VH
    BMC Public Health; 2002 Sep; 2():22. PubMed ID: 12241559
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Measles control in Maputo, Mozambique, using a single dose of Schwarz vaccine at age 9 months.
    Cutts FT; Monteiro O; Tabard P; Cliff J
    Bull World Health Organ; 1994; 72(2):227-31. PubMed ID: 8205642
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two doses of measles vaccine reduce measles dealths.
    van den Ent M; Gupta SK; Hoekstra E
    Indian Pediatr; 2009 Nov; 46(11):933-8. PubMed ID: 19955576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Costs and Valuation of Health Impacts of Measles and Rubella Risk Management Policies.
    Thompson KM; Odahowski CL
    Risk Anal; 2016 Jul; 36(7):1357-82. PubMed ID: 26249331
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Health impact of measles vaccination in the United States.
    Bloch AB; Orenstein WA; Stetler HC; Wassilak SG; Amler RW; Bart KJ; Kirby CD; Hinman AR
    Pediatrics; 1985 Oct; 76(4):524-32. PubMed ID: 3931045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Measles epidemiology and outbreak response immunization in a rural community in Peru.
    Sniadack DH; Moscoso B; Aguilar R; Heath J; Bellini W; Chiu MC
    Bull World Health Organ; 1999; 77(7):545-52. PubMed ID: 10444877
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of two dose measles vaccination in a community setting.
    Phadke MA; Bhargava I; Dhaigude P; Bagade A; Biniwale MA; Kurlekar SU
    Indian Pediatr; 1998 Aug; 35(8):723-5. PubMed ID: 10216565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The living and health conditions of Palestinian children].
    Riv Inferm; 1992; 11(4):247-52. PubMed ID: 1296273
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival of previously measles-vaccinated and measles-unvaccinated children in an emergency situation: an unplanned study.
    Aaby P; Garly ML; Balé C; Martins C; Jensen H; Lisse I; Whittle H
    Pediatr Infect Dis J; 2003 Sep; 22(9):798-805. PubMed ID: 14506371
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Global eradication of measles: an epidemiologic and economic evaluation.
    Levin A; Burgess C; Garrison LP; Bauch C; Babigumira J; Simons E; Dabbagh A
    J Infect Dis; 2011 Jul; 204 Suppl 1():S98-106. PubMed ID: 21666220
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Costs and benefits of measles and mumps immunization in Austria.
    Wiedermann G; Ambrosch F
    Bull World Health Organ; 1979; 57(4):625-9. PubMed ID: 118811
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Seroconversion after measles vaccination at nine and fifteen months of age.
    Işik N; Uzel N; Gökçay G; Kiliç A; Yilmaz G; Sadikoğlu B; Diri S
    Pediatr Infect Dis J; 2003 Aug; 22(8):691-5. PubMed ID: 12913768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A benefit-cost analysis of a childhood varicella vaccination programme.
    Preblud SR; Orenstein WA; Koplan JP; Bart KJ; Hinman AR
    Postgrad Med J; 1985; 61 Suppl 4():17-22. PubMed ID: 3939152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.